TY  - GEN
AU  - Pirazzoli,Valentina
AU  - Nebhan,Caroline
AU  - Song,Xiaoling
AU  - Wurtz,Anna
AU  - Walther,Zenta
AU  - Cai,Guoping
AU  - Zhao,Zhongming
AU  - Jia,Peilin
AU  - de Stanchina,Elisa
AU  - Shapiro,Erik M
AU  - Gale,Molly
AU  - Yin,Ruonan
AU  - Horn,Leora
AU  - Carbone,David P
AU  - Stephens,Philip J
AU  - Miller,Vincent
AU  - Gettinger,Scott
AU  - Pao,William
AU  - Politi,Katerina
TI  - Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1
SN  - 2211-1247
PY  - 2015///0420
KW  - Adenocarcinoma
KW  - drug therapy
KW  - Adenocarcinoma of Lung
KW  - Afatinib
KW  - Animals
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - pharmacology
KW  - Cell Line, Tumor
KW  - Cetuximab
KW  - Drug Resistance, Neoplasm
KW  - ErbB Receptors
KW  - genetics
KW  - Humans
KW  - Lung Neoplasms
KW  - Mechanistic Target of Rapamycin Complex 1
KW  - Mice
KW  - Mice, Nude
KW  - Mice, Transgenic
KW  - Multiprotein Complexes
KW  - metabolism
KW  - Mutation
KW  - Quinazolines
KW  - Random Allocation
KW  - TOR Serine-Threonine Kinases
KW  - Xenograft Model Antitumor Assays
N1  - Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.celrep.2014.04.014
ER  -